세포 기반 어세이 시장 보고서 : 제품·서비스별, 기술별, 용도별, 최종사용자별, 지역별(2026-2034년)

The global cell-based assay market size reached USD 25.7 Billion in 2025. Looking forward, the market is projected to reach USD 46.6 Billion by 2034, exhibiting a growth rate (CAGR) of 6.61% during 2026-2034. The market is driven by the growing demand for advanced drug discovery solutions, particularly in the context of rising chronic disease prevalence and the need for targeted therapies. Increasing emphasis on personalized medicine, coupled with innovations in 3D cell cultures and high-throughput screening technologies, is accelerating the adoption of cell-based assays. Additionally, the ability of these assays to enhance early-stage toxicity prediction and streamline pharmaceutical R&D is drawing substantial investment, further augmenting the cell-based assay market share.

A cell-based assay, also known as a cellular assay, is a laboratory technique that is used in various scientific and medical fields to assess the biological activity of cells in response to specific substances or conditions. It comprises culturing living cells in controlled environments and exposing them to various stimuli, such as drugs, compounds, or environmental factors. As it allows researchers to gain critical insights into the effects of the tested substances on cellular function by monitoring changes in cell behavior, such as cell viability or the expression of specific biomarkers, the demand for cell-based assay is increasing worldwide.

At present, the rising adoption of cell-based assays for drug discovery, toxicology studies, disease modeling, and understanding cellular mechanisms is supporting the cell-based assay market growth. Besides this, the increasing need to evaluate the potential efficacy and safety of pharmaceutical compounds is strengthening the growth of the market. Additionally, the growing demand for cell-based assays, as they enable researchers to identify potential adverse effects early in the development process and assess the toxicity of chemicals, is positively influencing the market. Apart from this, increasing incidences of numerous chronic diseases, such as cancer, diabetes, and autoimmune disorders, among individuals around the world are offering lucrative growth opportunities to industry investors. Furthermore, the rising need to assess the impact of chemicals and pollutants on plant and aquatic systems is bolstering the growth of the market.

CELL-BASED ASSAY MARKET TRENDS/DRIVERS:

Rising demand for novel therapies to address various diseases

The rising focus on drug discovery and development, along with the increasing demand for novel therapies to address various chronic diseases among individuals across the globe, is contributing to the growth of the market. In addition, cell-based assays enable researchers to screen and evaluate a vast number of potential drug candidates quickly and efficiently. By exposing cells to different compounds, scientists can assess their impact on cellular behavior, including their efficacy and safety profiles. Apart from this, there is an increase in the focus on precision medicine that necessitates a deep understanding of how drugs interact with specific cellular pathways, thereby creating a positive cell-based assay market outlook. Moreover, these assays provide a platform for tailoring drug treatments to individual patient profiles.

Increasing focus on personalized medicines

The rising focus on personalized medicines among the masses is supporting the growth of the market. In line with this, healthcare facilities are rapidly focusing on treatment solutions that are customized to suit the genetic, molecular, and cellular characteristics of individual patients. Besides this, cell-based assays allow researchers to evaluate the response of patient-derived cells to various drugs and treatments and enable the identification of the most effective therapies while minimizing potential side effects. According to the cell-based assay market research report, personalized medicine not only improves treatment outcomes but also reduces healthcare costs by avoiding ineffective treatments. As a result, there is an increase in the adoption of cell-based assays in both clinical and research settings, as they provide a powerful tool for tailoring medical interventions to the specific needs of patients.

Innovations in cell culture technologies

Advancements in cell culture techniques are enhancing the capabilities of cell-based assays. 3D cultures and organoids allow researchers to study cell behavior closer to the human body to improve the accuracy of drug screening and toxicity testing, which is offering a positive market outlook. Additionally, microfluidics and lab-on-a-chip technologies enable the development of miniaturized and automated cell-based assays that assist in increasing throughput and efficiency in drug discovery. In line with this, the integration of these advanced cell culture technologies into cell-based assays aids in enhancing their relevance and applicability, which makes them suitable tools for understanding disease mechanisms and evaluating drug candidates with greater precision.

CELL-BASED ASSAY INDUSTRY SEGMENTATION:

Breakup by Product and Services:

• Consumables
  • Reagents and Media
  • Cells and Cell Lines
  • Probes and Labels
• Instruments
  • Microplates
  • Microplate Readers
  • High Throughput Screening
  • Liquid Handling Systems
• Services
• Software

Consumables represent the largest market segment

Breakup by Technology:

• Automated Handling
• Flow Cytometry
• Label-Free Detection
• High-Throughput Screening
• Others

High-throughput screening accounts for the majority of the market share

Breakup by Application:

• Drug Discovery
• Basic Research
• ADME Studies
• Predictive Toxicology
• Others

Drug discovery dominates the market share

Breakup by End-User:

• Pharmaceutical and Biotechnology Companies
• Academic and Government Institutions
• Contract Research Organizations
• Others

Pharmaceutical and biotechnology companies hold the biggest market share

Breakup by Region:

• North America
• Europe
• Asia Pacific
• Middle East and Africa
• Latin America

North America exhibits a clear dominance, accounting for the largest cell-based assay market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America held the biggest market share due to the increasing demand for advanced assay technologies and consumables. In addition, the rising development of novel cell-based assay techniques is bolstering the growth of the market in the region. Apart from this, the growing focus on drug safety is positively influencing the market. In line with this, stringent regulatory standards are propelling the growth of the market in the North America region.

COMPETITIVE LANDSCAPE:

Major players are developing innovative assay technologies, such as novel reagents, assay kits, and platforms. This involves creating more physiologically relevant cell models to improve assay sensitivity and enhance automation and data analysis capabilities. In line with this, companies are expanding their product portfolios to cater to a wide range of applications. This includes offering assays tailored for specific targets, pathways, or disease models, and developing specialized kits for toxicity testing and drug screening. Apart from this, key manufacturers are providing customized assay development services and are working closely with clients to tailor assays to their specific research needs, which is offering a positive market outlook.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

• Beckman Coulter, Inc.
• Bio-Rad Laboratories, Inc
• Cell Biolabs, Inc.
• Cell Signaling Technology, Inc
• Charles River Laboratories
• Corning Incorporated
• DH Life Sciences, LLC
• Eurofins DiscoverX
• Lonza
• Merck KGaA
• Promega Corporation
• Thermo Fisher Scientific Inc

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Cell-Based Assay Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Breakup by Product and Services
• 5.5 Market Breakup by Technology
• 5.6 Market Breakup by Application
• 5.7 Market Breakup by End-User
• 5.8 Market Breakup by Region
• 5.9 Market Forecast
• 5.10 SWOT Analysis
  • 5.10.1 Overview
  • 5.10.2 Strengths
  • 5.10.3 Weaknesses
  • 5.10.4 Opportunities
  • 5.10.5 Threats
• 5.11 Value Chain Analysis
• 5.12 Porters Five Forces Analysis
  • 5.12.1 Overview
  • 5.12.2 Bargaining Power of Buyers
  • 5.12.3 Bargaining Power of Suppliers
  • 5.12.4 Degree of Competition
  • 5.12.5 Threat of New Entrants
  • 5.12.6 Threat of Substitutes

6 Market Breakup by Product and Services

• 6.1 Consumables
  • 6.1.1 Reagents and Media
    • 6.1.1.1 Market Trends
    • 6.1.1.2 Market Forecast
  • 6.1.2 Cells and Cell Lines
    • 6.1.2.1 Market Trends
    • 6.1.2.2 Market Forecast
  • 6.1.3 Probes and Labels
    • 6.1.3.1 Market Trends
    • 6.1.3.2 Market Forecast
• 6.2 Instruments
  • 6.2.1 Microplates
    • 6.2.1.1 Market Trends
    • 6.2.1.2 Market Forecast
  • 6.2.2 Microplate Readers
    • 6.2.2.1 Market Trends
    • 6.2.2.2 Market Forecast
  • 6.2.3 High Throughput Screening
    • 6.2.3.1 Market Trends
    • 6.2.3.2 Market Forecast
  • 6.2.4 Liquid Handling Systems
    • 6.2.4.1 Market Trends
    • 6.2.4.2 Market Forecast
• 6.3 Services
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Software
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Technology

• 7.1 Automated Handling
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Flow Cytometry
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Label-Free Detection
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 High-Throughput Screening
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by Application

• 8.1 Drug Discovery
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Basic Research
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 ADME Studies
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Predictive Toxicology
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Others
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Market Breakup by End-User

• 9.1 Pharmaceutical and Biotechnology Companies
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Academic and Government Institutions
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Contract Research Organizations
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Others
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Europe
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Asia Pacific
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast
• 10.4 Middle East and Africa
  • 10.4.1 Market Trends
  • 10.4.2 Market Forecast
• 10.5 Latin America
  • 10.5.1 Market Trends
  • 10.5.2 Market Forecast

11 Competitive Landscape

• 11.1 Market Structure
• 11.2 Key Players
• 11.3 Profiles of Key Players
  • 11.3.1 Beckman Coulter, Inc.
  • 11.3.2 Bio-Rad Laboratories, Inc
  • 11.3.3 Cell Biolabs, Inc.
  • 11.3.4 Cell Signaling Technology, Inc
  • 11.3.5 Charles River Laboratories
  • 11.3.6 Corning Incorporated
  • 11.3.7 DH Life Sciences, LLC
  • 11.3.8 Eurofins DiscoverX
  • 11.3.9 Lonza
  • 11.3.10 Merck KGaA
  • 11.3.11 Promega Corporation
  • 11.3.12 Thermo Fisher Scientific Inc